Development of Myelodysplastic Syndrome and Acute Myeloid Leukemia 15 Years after Hydroxyurea Use in a Patient with Sickle Cell Anemia by Baz, Walid et al.
Clinical Medicine Insights: Oncology 2012:6 149–152
doi: 10.4137/CMO.S8810
This article is available from http://www.la-press.com.
© the author(s), publisher and licensee Libertas Academica Ltd.
This is an open access article. Unrestricted non-commercial use is permitted provided the original work is properly cited.
Open Access
Full open access to this and 
thousands of other papers at 
http://www.la-press.com.
Clinical Medicine Insights: Oncology
CASe repOrT
Clinical Medicine Insights: Oncology 2012:6  149
Development of Myelodysplastic syndrome and Acute  
Myeloid Leukemia 15 Years after Hydroxyurea  
Use in a patient with sickle cell Anemia
1Hematology/Oncology department, Appalachian regional Healthcare system, 306 Hospital Drive, South Williamson,  
KY 41503. 2pathology and Medicine Department, Myeloproliferative Disorders program, The Tisch Cancer Institute, 
Mount Sinai Medical Center, One Gustave L Levy place, New York, NY, 10029. 3Internal Medicine Department, 
4pathology Department, 5Hematology/Oncology Department, Staten Island University Hospital, 256 Mason Avenue, 
Staten Island, NY 10305. Corresponding author email: walidbazmd@gmail.com
Abstract: We report a 41 year old male with sickle cell disease who developed a myelodysplastic syndrome and acute myeloid leukemia 
with complex karyotype involving chromosomes 5, 7 and 17 after 15 years of hydroxyurea treatment. He responded poorly to induction 
chemotherapy with cytarabine/idarubicin followed by high dose cytarabine and succumbed to neutropenic sepsis. Multiple system-
atic reviews, observational studies and clinical trials were conducted to identify the toxicity profile of hydroxurea. Only six cases of 
leukemia/myelodysplastic syndrome were identified in patients with sickle cell anemia treated with hydroxyurea. Subsequently, it was 
concluded that hydroxyurea is not leukemogenic. However, it was noted that most of the published studies had only up to 9 years of 
follow-up. Our patient was started on hydroxyurea in 1990, before the widespread use of the drug and took hydroxyurea for 15 years. 
His presentation may reflect an outcome otherwise not yet observed because of the short follow-up of prior studies. We believe that the 
leukemogenic risk of hydroxyurea should be discussed with the patients and their families. Studies evaluating the adverse effects of 
hydroxyurea should have longer follow-up before definitive conclusions are drawn.
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case report
A 21 year old African–American male first presented 
to the adult hematology service with frequent sickle 
cell  crises.  Despite  multiple  exchange  transfusions 
his  sickle  cell  disease  (SCD)  continued  to  require 
hospitalization  for  management  of  painful  crises. 
The patient did not have any significant past medical 
  history but his sister had Gaucher disease. At age 26, 
he  was  begun  on  hydroxyurea  (HU).  Significant 
improvement in his crises occurred with reduction in 
hospital admissions, from more than 14 admissions 
per year to 3 admissions per year. The patient took 
HU for 15 years. The dose of HU ranged from 1.5 
to 2 grams per day. At age 41, the drug was discontin-
ued because of refractory pancytopenia. A bone mar-
row biopsy revealed Refractory Anemia with Excess 
Blasts-2 according to the World Health Organization 
classification (Fig. 1). Myeloblasts (15% of myeloid 
cells) were CD33, CD34, CD117 and CD68 positive 
by immunohistochemistry. Flow cytometry was not 
performed because the aspirate was dry. The patient 
was referred for a second opinion and a repeat bone 
marrow biopsy was performed 34 days after the first 
biopsy which showed progression of myelodysplastic 
syndrome to acute myeloid leukemia (AML) with 68% 
myeloblasts on flow cytometry. All 20 cells examined 
from the bone marrow aspirate had 42XY with com-
plex cytogenetics including, t(5;18), del(7)(q21) and 
-17 (Fig. 2). A peripheral blood sample revealed a 
white blood cell count of 14 × 109/L with 41% blasts. 
The patient underwent induction chemotherapy with 
cytarabine and idarubicin. A peripheral blood flow 
cytometry done 2 months after induction chemother-
apy due to persistent pancytopenia revealed the pres-
ence of CD33+/CD34+/CD117+ myeloblasts (2.6%). 
Subsequent  treatment  included  high  dose  cytara-
bine with a goal of remission prior to bone marrow 
  transplantation. His hospital course was complicated 
by  pancytopenia,  sepsis,  subarachnoid  hemorrhage 
and respiratory failure. He died at age 41.
Discussion
HU is the only approved medication for the   treatment 
of sickle cell disease. It has been shown to signifi-
cantly modify the course of SCD with up to a 40% 
reduction  in  mortality  after  9  years  of  follow-up.1 
Most adverse effects of hydroxyurea are mild and 
include:  rash,  hyperpigmentation,  nail  changes, 
cutaneous  ulcerations,  alopecia,  mucositis,  nausea, 
  vomiting,   diarrhea, fever, fatigue, myelosuppression, 
drowsiness, and headache. Other rare adverse effects 
include:  hepatic  failure,  renal  failure,  interstitial 
pneumonitis and azoospermia. Because HU impairs 
the  repair  of  damaged  DNA,  clinicians  have  been 
concerned that long term exposure to HU may lead 
to an accumulation of acquired DNA mutations and 
eventual leukemic transformation.
To clarify the toxicity profile of HU, the Johns 
Hopkins University Evidence-based Practice   Center 
reviewed  numerous  randomized  clinical  trials, 
observational studies, and case reports of patients 
with  MPD  or  SCD  on  HU.  In  the  MPD  group, 
there were no increased cases of leukemia/MDS in 
patients on HU compared to patients not receiving 
the drug.2 To our knowledge and based on the John 
Hopkins review, only six patients with SCD on HU 
were  reported  to  subsequently  develop  leukemia/
MDS:  a  10  year  old  female  with  a  Philadelphia 
chromosome acute lymphoblastic leukemia (ALL) 
after 1.5 years of HU treatment,3 a 14 year old male 
with ALL after 3 months of HU treatment,4 a 21 year 
old female with acute promyelocytic leukemia after 
8 years of HU treatment,5 a 25 year old female with 
AML  after  2  years  of  HU  treatment,6  a  27  year 
old  female  with AML/MDS  after  8  years  of  HU 
treatment,7 and a 42 year old female with AML after 
Figure 1. Bone marrow biopsy and aspirate. (A) Low power magnification 
showing a hypercellular marrow for age (.90%) and Gaucher/  pseudo-
Gaucher  cells  (arrow).  (B)  High  power  magnification  showing  blasts 
with large nuclei and prominent nucleoli. (c) High power magnification 
showing a dysplastic megakaryocyte with multiple small lobes seem-
ingly disconnected. (D) High power magnification showing a   dysplastic 
eryrthroblast with nuclear budding.Leukemogenic risk of hydroxyurea
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6 years of HU   treatment.8   Cytogenetic analysis was 
only reported in the 25 year old female, who had a 
normal karyotype. Based on this large review, it was 
concluded that there was evidence, qualified as being 
low grade, that HU treatment is not associated with 
leukemia.2 The evidence was qualified as low grade 
as most of the studies reviewed had only 9 years of 
follow-up. To our knowledge, only one study had 
more than 9 years follow-up. In this single center 
trial, 26 patients were followed-up for more than 
15 years, 12 of whom were followed for 17 years. 
Of 131 patients enrolled in this study and taking 
HU,  none  developed  MDS,  leukemia  or    cancer.9 
Our patient was treated with HU for 15 years. Given 
the extended duration of follow-up, his presentation 
may reflect an outcome otherwise not yet observed 
in most of the previous studies which are shorter 
in  duration.  He  was  not  exposed  to  radiation  or 
chemicals,  did  not  have  a  myeloproliferative 
disorder,  or  any  underlying  identifiable  genetic 
predisposition that explains his progression to AML/
MDS at the age of 41. Pseudo-Gaucher cells may 
be found in the bone marrow biopsies of patients 
with MDS or leukemia which explain the pseudo-
Gaucher cells seen in the patient’s bone marrow.10 
Gaucher disease is not known to be a predisposing 
factor  for  the  development  of  AML/MDS.11  The 
unique aspect of our case is that complex karyotype 
involving  chromosome  5,  7  or  17  were  never 
reported in a sickle cell patient on HU treatment. 
Chemotherapy or radiation induced leukemia/MDS 
is associated with monosomy or deletion of long arm 
of chromosome 5 or 7.12–14 Recently, deletion of the 
whole chromosome 17 or its short arm was found 
to be specifically associated with HU treatment in 
patients with MPDs.15–18 This “17p- syndrome” results 
from deletion of the tumor suppressor gene p53.16–18 
Our patient had not only monosomy 17 consistent 
with HU related MDS but had also, deletion 7q, and 
multiple  other  complex  structural  rearrangements 
suggestive  of  chemotherapy  induced  leukemia/
MDS. HU is currently used in children with SCD. 
Numerous  observational  and  randomized  clinical 
trials conducted in children, demonstrated decreases 
in the rates of hospitalization, painful crises, acute 
chest syndrome, stroke, and cognitive development 
without  affecting  growth.19  Many  children  with 
SCD are being enrolled in clinical trials involving 
HU treatment. We are concerned that this population 
will be exposed to HU for a long period of time 
which may increase its potential leukemogenic risk. 
Our case highlights the observation that short-term 
studies cannot provide strong evidence for toxicities 
that may require years to be observed. We believe 
that the leukemogenic risk of hydroxyurea should be 
discussed with the patients and their families. Studies 
evaluating the adverse effects of HU should have 
longer follow-up before definitive conclusions are 
Figure 2. 42, XY, -3, +der(5)t(5;18)(p12;q11.2), del(7)(q21), add(8)(p23), der(9)t(9;14)(q34;q11), -11, add(12)(p13), -13, del(14)(q11), -17, add(18)(q22), 
der(18)t(11;18)(q14;q23), der(19)t(5;19)(p12;p12) karyotype.publish with Libertas Academica and 
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drawn. Physicians and patients should consider all 
risks and benefits prior to initiating HU treatment.
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